Contribution of TP53 and MDM4 Genetic Polymorphisms as a Risk Factor in Non-Hodgkin Lymphoma in Adult Egyptian Patients.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2025-07-03 eCollection Date: 2025-01-01 DOI:10.1177/11795549251352047

Eman A Helal, Naglaa M Hassan, Mahmoud M Kamel, Mahmoud A Amer, Roxan E Shafik

{"title":"Contribution of TP53 and MDM4 Genetic Polymorphisms as a Risk Factor in Non-Hodgkin Lymphoma in Adult Egyptian Patients.","authors":"Eman A Helal, Naglaa M Hassan, Mahmoud M Kamel, Mahmoud A Amer, Roxan E Shafik","doi":"10.1177/11795549251352047","DOIUrl":null,"url":null,"abstract":"Background: Non-Hodgkin Lymphoma (NHL) is an increasingly prevalent hematological malignancy in Egypt, highlighting the need for a better understanding of its genetic risk factors. The TP53 and MDM4 genes play critical roles in cellular homeostasis and cancer development. This study aimed to assess the frequency of the TP53 (SNP rs1042522) Arg72Pro and MDM4 (SNP rs4245739) A > C polymorphisms as potential risk factors for NHL in adult Egyptian patients.Methods: A case-control study was conducted involving 80 adult NHL patients and 100 control age- and sex-matched healthy controls. Genotyping for the TP53 (rs1042522) Arg72Pro and MDM4 (rs4245739) A > C polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.Results: A significant association was found between the homozygous TP53 Pro/Pro genotype and increased susceptibility to NHL (47.5% in patients vs 4.0% in controls; P < .001), as well as a higher frequency of the mutant C allele among NHL cases (63.8% vs 28.0%; P < .001). In contrast, no significant association was observed between MDM4 polymorphisms and NHL risk. In addition, analysis of treatment outcomes revealed no statistically significant differences in overall survival or progression-free survival based on TP53 or MDM4 genotypes.Conclusions: These findings suggest that the TP53 Arg72Pro polymorphism is a significant genetic marker for NHL susceptibility in the Egyptian population, while MDM4 polymorphisms do not appear to contribute to disease risk. Further studies are warranted to elucidate the genetic mechanisms underlying NHL and to explore their implications for risk stratification and therapeutic strategies.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251352047"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227885/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549251352047","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Non-Hodgkin Lymphoma (NHL) is an increasingly prevalent hematological malignancy in Egypt, highlighting the need for a better understanding of its genetic risk factors. The TP53 and MDM4 genes play critical roles in cellular homeostasis and cancer development. This study aimed to assess the frequency of the TP53 (SNP rs1042522) Arg72Pro and MDM4 (SNP rs4245739) A > C polymorphisms as potential risk factors for NHL in adult Egyptian patients.

Methods: A case-control study was conducted involving 80 adult NHL patients and 100 control age- and sex-matched healthy controls. Genotyping for the TP53 (rs1042522) Arg72Pro and MDM4 (rs4245739) A > C polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

Results: A significant association was found between the homozygous TP53 Pro/Pro genotype and increased susceptibility to NHL (47.5% in patients vs 4.0% in controls; P < .001), as well as a higher frequency of the mutant C allele among NHL cases (63.8% vs 28.0%; P < .001). In contrast, no significant association was observed between MDM4 polymorphisms and NHL risk. In addition, analysis of treatment outcomes revealed no statistically significant differences in overall survival or progression-free survival based on TP53 or MDM4 genotypes.

Conclusions: These findings suggest that the TP53 Arg72Pro polymorphism is a significant genetic marker for NHL susceptibility in the Egyptian population, while MDM4 polymorphisms do not appear to contribute to disease risk. Further studies are warranted to elucidate the genetic mechanisms underlying NHL and to explore their implications for risk stratification and therapeutic strategies.

Abstract Image

查看原文本刊更多论文

TP53和MDM4基因多态性作为埃及成年非霍奇金淋巴瘤的危险因素

背景：非霍奇金淋巴瘤（NHL）在埃及是一种日益普遍的血液系统恶性肿瘤，强调需要更好地了解其遗传风险因素。TP53和MDM4基因在细胞稳态和癌症发展中起着关键作用。本研究旨在评估TP53 (SNP rs1042522) Arg72Pro和MDM4 (SNP rs4245739) A > C多态性的频率作为埃及成年NHL患者的潜在危险因素。方法：采用病例对照研究，纳入80例成年NHL患者和100例年龄和性别匹配的健康对照。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法对TP53 (rs1042522) Arg72Pro和MDM4 (rs4245739) A > C多态性进行基因分型。结果：纯合子TP53 Pro/Pro基因型与NHL易感性增加之间存在显著关联(患者为47.5%，对照组为4.0%；结论：这些发现表明，TP53 Arg72Pro多态性是埃及人群NHL易感性的重要遗传标记，而MDM4多态性似乎与疾病风险无关。需要进一步的研究来阐明NHL的遗传机制，并探讨其对风险分层和治疗策略的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.